Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (NASDAQ: CODX) reported Q3 2024 financial results with revenue of $0.6 million, down from $2.5 million in the prior year. The company posted a net loss of $9.7 million ($0.32 per share) compared to $6.0 million ($0.20 per share) in 2023. Operating expenses decreased 5% to $10.6 million. The company maintains a strong cash position of $37.7 million. Business highlights include expansion of vector control business to 15 states and preparation for inauguration of oligonucleotide manufacturing facility in India. The company continues FDA dialogue for 510(k) application review and advances its test pipeline development.
Co-Diagnostics (CODX) announced its participation in MEDICA 2024, the world's largest medical B2B trade fair, scheduled for November 11-14 in Düsseldorf, Germany. The event attracts 83,000 visitors and over 5,300 exhibitors from nearly 70 countries.
The company will showcase its PCR diagnostic products and Co-Primers® technology at Booth #3 D15-1. Additionally, they will deliver a presentation titled 'Advancing POC/OTC Diagnostics: Innovations in Test Development for the Co-Dx PCR Platform' on November 13 at 12:05 PM CET in Hall 8A Booth G40. The presentation will focus on their upcoming Co-Dx PCR platform, which is currently under FDA review.
Co-Diagnostics (NASDAQ: CODX) announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day, featuring CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. The event will be accessible via webcast on the company's investor relations website and through conference call lines. A recording will be available later on the company's website for those unable to attend live.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in Africa Health/Medlab Africa in Cape Town, South Africa from October 22-24, 2024. The conference is described as the largest gathering of healthcare companies in the sub-Saharan region. Co-Dx views this trade show as an opportunity to gain insight into markets expected to play a significant role in the company's future.
The company highlighted the importance of the African market, citing a WHO report estimating 2.5 million tuberculosis cases in the African Region in 2021. Co-Dx is developing several infectious disease tests, including one for TB, on its upcoming Co-Dx™ PCR at-home and point-of-care platform. The company also mentioned its Logix Smart® Mpox (2-Gene) RUO test, which is expected to retain full reactivity against known mpox strains.
Interested parties can visit Co-Dx at Booth H1/B1 during the conference.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) has announced its participation in the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo on October 2-3, 2024. The event will take place at the Mountain America Expo Center in Sandy, Utah.
The company will host Booth 300, showcasing its upcoming Co-Dx PCR platform, including a menu of at-home and point-of-care tests in development. The convention caters to executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living, and intermediate care facilities.
Interested parties are invited to visit Co-Diagnostics' booth to learn more about their diagnostic products and their applications in the healthcare sector. It's important to note that the Co-Dx PCR platform, including associated tests and software, is currently under review by the FDA and other regulatory bodies and is not yet available for sale.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the World Trade Center (WTC) Utah trade mission to South Korea and Japan from September 24-October 5, 2024. The company will join Utah Governor Cox and the Governor's Office of Economic Opportunity delegation for life sciences and innovation. This mission aims to expand Co-Dx's international relationships as it prepares to introduce a new PCR diagnostic platform for at-home and point-of-care use.
Co-Diagnostics has a history of international ventures, including a joint venture in India established in 2017 and a network of distributors, partners, and customers in over 50 countries. The company's CEO, Dwight Egan, emphasized the importance of building global relationships to improve access to care and increase the availability of high-quality PCR diagnostics worldwide.
Co-Diagnostics, Inc. (CODX) has completed an updated in silico analysis of its Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test. The analysis shows that the test should maintain full reactivity against mpox strains circulating over the past year, including the more transmissible and severe clade Ib. This comes as the Africa CDC declared mpox a Public Health Emergency of Continental Security on August 13, 2024, followed by the WHO declaring it a public health emergency of international concern. As of August 27, 2024, Africa reported over 22,800 mpox cases and 622 deaths. The Company's 2-gene mpox test was previously shown to perform better at detecting mpox from saliva samples compared to other assays in a study published in December 2023.
Co-Diagnostics, Inc. (CODX) announced its participation in the 16th Annual Next Generation Dx Summit in Washington, D.C. from August 19-21, 2024. The company will sponsor, present, and host a booth at this event, which focuses on diagnostic advancement and technology innovation.
CEO Dwight Egan will present on the company's upcoming PCR platform, currently under FDA review, in a luncheon presentation titled "Co-Dx PCR Platform: The Future of Accessible Diagnostics" on August 19 at 12:15 PM ET.
Attendees can visit Booth #26 to learn about the Co-Dx PCR testing platform and the Co-Dx Logix Smart® suite of clinical laboratory solutions, including Research Use Only (RUO) tests for mpox virus. The company's mpox test was featured in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December 2023.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported its Q2 2024 financial results, showing improvements despite ongoing losses. Revenue increased to $2.7 million from $0.2 million in the prior year, primarily due to milestone achievements in grant agreements. The company reduced its operating loss to $7.7 million from $12.0 million in 2023, with a net loss of $7.6 million ($0.25 per share) compared to $8.9 million ($0.31 per share) last year.
Key highlights include submitting a 510(k) application to the FDA for the Co-Dx™ PCR Pro™ Platform, inaugurating a new manufacturing facility, and expanding vector control technology to Nevada. The company maintains a strong cash position of $44.9 million as of June 30, 2024.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting in Chicago from July 28-August 1, 2024. The company will host a booth and deliver a presentation on July 30 at 2:00 PM, focusing on their new Co-Dx™ PCR platform for at-home and point-of-care diagnostics. This platform aims to address the global diagnostics gap, with potential applications including tuberculosis (TB) testing.
Co-Dx recently submitted an FDA 510(k) application for a COVID-19 test using this platform. The company will showcase the Co-Dx PCR Pro™ instrument at Booth 2879 and present a scientific poster on July 31. CEO Dwight Egan and Executive VP Joseph Featherstone will discuss Co-Dx's role in the initiative to end TB by 2030. The new platform and associated tests are currently under FDA review and not yet available for sale.